Inclusion criteria
1. Between 18 and 75 years of age
2. Willing and able to give written informed consent
3. Clinically definite Multiple Sclerosis
4. On Glatiramer Acetate for at least 3 months
5. No relapse within 3 months
Exclusion criteria
1. No MS treatment or treated with beta-interferon (Avonex, Rebif, Betaseron), Tysabri, Fingolimod, Tecfidera, Aubagio, Lemtrada, corticosteroids, or other immunosuppressive or immunomodulatory therapy in the previous 3 months
2. Have taken GlcNAc or glucosamine in the previous 3 months
3. Unwilling or unable to comply with the study visit requirements
4. Allergy to shellfish
5. Weight less than 110 lb. (50 kg) or greater than 220 lb. (100 kg)
6. Have a history of Type 1 diabetes, Type 2 diabetes poorly controlled (HbA1c > 6.5% at first visit), type 2 diabetes on insulin, vascular disease, coronary artery disease, stroke, or transient ischemic attack, cancer, organ transplant, bleeding disorder, chronic respiratory disease, including asthma, chronic renal failure, chronic liver disease, or seizure disorder
7. Any clinically significant abnormalities on clinical labs
8. Pregnant as confirmed by serum pregnancy test, less than 6-month postpartum, breast feeding postpartum, or attempting to conceive (all forms of FDA approved contraception permitted)